ABSTRACT
Development of an effective human immunodeficiency virus (HIV) vaccine is one of the primary goals of global acquired immunodeficiency syndrome (AIDS) research. Despite progress in prevention of and powerful drug combinations to treat HIV infection, an estimated 16,000 people become infected every day. Over 90% of new infections occur in developing countries, in which recent medical advances are not immediately applicable or affordable. The best hope for these countries is the development of a safe, effective, accessible HIV vaccine. There is now growing optimism among scientists that an AIDS vaccine may be possible (1).
